Patent: 6,264,957
Summary for Patent: 6,264,957
| Title: | Product of infectious respiratory syncytial virus from cloned nucleotide sequences |
| Abstract: | Isolated polynucleotide molecules provide RSV genome and antigenomes, including that of human, bovine or murine RSV or RSV-like viruses, and chimera thereof. The recombinant genome or antigenome can be expressed with a nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large (L) polymerase protein, and an RNA polymerase elongation factor to produce isolated infectious RSV particles. The recombinant RSV genome and antigenome can be modified to produce desired phenotypic changes, such as attenuated viruses for vaccine use. |
| Inventor(s): | Peter L. Collins |
| Assignee: | HEALTH DEPARTMENT OF United States, , US Department of Health and Human Services |
| Application Number: | US08/720,132 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,264,957
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Llc | ZOSTAVAX | zoster vaccine live | For Injection | 125123 | May 25, 2006 | ⤷ Start Trial | 2016-09-27 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
